Navigation Links
Rigel to Present at UBS Global Life Sciences Conference
Date:9/17/2012

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the UBS Global Life Sciences Conference in New York City on Thursday, September 20th at 4:30 p.m. ET.

To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders.

Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
2. Rigel Announces Second Quarter 2012 Financial Results
3. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
4. Rigel Announces First Quarter 2012 Financial Results
5. Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
6. HeartWare Presentation at the UBS Global Life Sciences Conference to be Webcast
7. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
8. Depomed To Present At UBS Global Life Sciences Conference
9. Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
10. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
11. Abaxis, Inc. to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... 16, 2017 CBDRx, the world,s premiere nutraceutical ... phyto-nutrient rich hemp extract to Veteran,s groups across the ... proprietary hemp extract to Veteran,s groups across the United ... company in the world and through their passion, CBDRx ... spectrum phyto-nutrient rich hemp extract available. ...
(Date:1/14/2017)... SAN DIEGO , Jan. 14, 2017  Johnson & ... on behalf of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... 7, 2016, through October 31, 2016 (the "Class Period"). ... designs, manufactures, and markets orthopaedic reconstructive products, such as knee ... ...
(Date:1/13/2017)... , January 13, 2017 Constant ... of AIDS will collectively contribute to the demand for western ... reach a value of US$ 551.0 Mn by 2016 end. ... remain the most lucrative markets for western blotting, whereas ... market globally. ...
Breaking Medicine Technology:
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... San Francisco ... iTero Element, the latest in 3-D scanning device which is capable of taking digital ... latest advances in dentistry, such as CAD CAM restorations , in terms of ...
(Date:1/15/2017)... York, NY (PRWEB) , ... January 15, 2017 , ... ... strategic accounts in the United States for the asthma & allergy friendly mark. This ... America to independently test and identify consumer products to be more suitable for the ...
(Date:1/15/2017)... ... January 15, 2017 , ... Accreditation ... achieved accreditation for its specialty care services. Albertsons Companies is the largest ... care service for pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ dedication ...
(Date:1/15/2017)... ... January 14, 2017 , ... Wondering where to go ... delivered straight to your door for a romantic, lobster feast in the comfort of ... for Valentine's Day. The dinners will be featured until February 15th, 2017. , ...
(Date:1/14/2017)... , ... January 14, 2017 , ... ... distinctions among their expanding line of activated charcoal products. With more and more ... of categorizing their products according to how they cater to specific needs. , ...
Breaking Medicine News(10 mins):